iPSC - platform

An industry leading iPSC-based drug discovery platform  

Evotec has built an industrialised iPSC infrastructure that represents one of the largest and most sophisticated iPSC platforms in the industry. Evotec's iPSC platform has been developed over the last six years with the goal to industrialise iPSC-based drug screening in terms of throughput, reproducibility and robustness to reach the highest industrial standards. This effort was initially enabled by a research collaboration and licence agreement with Harvard University involving world-leading scientists at the Harvard Stem Cell Institute. More recently, Evotec has established collaborations with Celgene, Sanofi, DFG Research Center for Regenerative Therapies Dresden, Censo Biotechnologies and Fraunhofer IME-SP to support Evotec's broad iPSC platform. In addition, we are working together with a number of academic institutions to further broaden and strengthen our iPSC ambitions. 

Creating "patients in a dish"

Previous Next Show fullscreen
Key components of our high-quality iPSC-based drug discovery platform have already been established, with a strong focus on standardisation, scaling and QC:
  • High-quality iPS cell cultures at large scale (QC)
  • Industrial processes for the generation of patient-derived target cell types
  • Robust disease-relevant phenotypic readouts for screening
  • Panel of patient-derived genotypes for patient stratification

 

 

Fully integrated iPSC-based drug discovery platform established - from iPSCs to drug candidate and beyond

iPSC culture
Patient-derived disease models
Hit identification
Hit-to-lead/ Lead-optimisation
In vivo pharmacology
Access to iPSC lines
SC-derived disease relevant cell types
High-content screening
Cellular assays
PK/PD
Expansion & banking
Optimisation
Electrophysiology
Medicinal chemistry
Biomarker-driven in vivo disease models
Quality control standards
Scale up

Gene expression profiling

Target deconvolution
Biomarkers
Scale up
Automation
In vitro toxicity
iPSC culture Access to iPSC lines
Patient-derived disease models SC-derived disease relevant cell types
Hit identification High-content screening
Hit-to-lead/ Lead-optimisation Cellular assays
In vivo pharmacology PK/PD
iPSC culture Expansion & banking
Patient-derived disease models Optimisation
Hit identification Electrophysiology
Hit-to-lead/ Lead-optimisation Medicinal chemistry
In vivo pharmacology Biomarker-driven in vivo disease models
iPSC culture Quality control standards
Patient-derived disease models Scale up
Hit identification

Gene expression profiling

Hit-to-lead/ Lead-optimisation Target deconvolution
In vivo pharmacology Biomarkers
iPSC culture Scale up
Patient-derived disease models Automation
Hit identification
Hit-to-lead/ Lead-optimisation In vitro toxicity
In vivo pharmacology

Evotec is running multiple drug discovery programmes using human iPSCs:

  • Neurodegenerative diseases
    • Alzheimer`s disease 
    • Amyotrophic lateral sclerosis
    • Frontotemporal dementia
    • Huntington`s disease
    • Parkinson`s disease
  • Further drug discovery programmes in other disease areas are currently being set up

You might also be interested in

Our iPSC-based drug discovery alliance with Celgene Our strategic Diabetes alliance with Sanofi

Summary

  • Scalable iPSC culture
    • iPSC bank with > 200 patient-derived iPSC lines
    • Highest quality and QC standards for cultivation
  • Industry scale differentiation protocols deliver high-quality neurons/beta cells
    • Characterisation of specific markers
    • Formation of functional neuronal networks/beta cells
    • Cryopreservation of large batches for screening
    • Differentiation protocols broadly applicable to iPSC lines from different patients
    • Robust and screenable iPSC-based assays in 384-well
  • Novel iPSC-derived cell types currently under development
  • Maximised throughput on 384-well automation platform

Contact us

Evotec

Business Development

T +44.(0)1235.86 15 61 F +44.(0)1235.86 31 39 vCard
TOP